Literature DB >> 7386498

Cell-mediated immunity to collagen and collagen alpha chains in rheumatoid arthritis and other rheumatic diseases.

J M Stuart, A E Postlethwaite, A S Townes, A H Kang.   

Abstract

Peripheral blood mononuclear cells from patients with rheumatoid arthritis, gout, ankylosing spondylitis and degenerative joint disease were cultured in the presence of native types I, II and III collagens and alpha chains from each of these types of collagen. The culture supernatant fluids were harvested and assayed for lymphocyte-derived chemotatic factor for monocytes. Reactions to one or more of the native collagens was found in 50 per cent (10 of 20) of the patients with rheumatoid arthritis, 20 per cent (two of 10) of the patients with gout and ankylosing spondylitis but in none of the 10 patients with degenerative joint disease or in normal subjects. Reaction to one or more alpha chains was found in 90 per cent (18 of 20) of the patients with rheumatoid arthritis, 60 per cent (six of 10) of the patients with gout, 50 per cent (five of 10) of the patients with ankylosing spondylitis, 30 per cent (three of 10) of the patients with degenerative joint disease and in 10 per cent of the normal subjects (one of 10). All the reactions were quantiatively stronger in patients with rheumatoid arthritis. These results indicate that patients with rheumatoid arthritis have cell-mediated immunity to homologous native and denatured collagens but that the reaction is not specific for rheumatoid arthritis. Some patients with gout, ankylosing spondylitis and degenerative joint disease also have low levels of immunity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7386498     DOI: 10.1016/0002-9343(80)90494-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Heberden Oration 1980: aspects of the cell biology of the rheumatoid synovial lesion.

Authors:  S M Krane
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

Review 2.  Cytokine modulation of chondrocyte metabolism--in vivo and in vitro effects of piroxicam.

Authors:  J H Herman; A M Appel; R C Khosla; K S Kelch; E V Hess
Journal:  Inflammation       Date:  1984-06       Impact factor: 4.092

3.  In vitro suppression of fibroblast growth inhibitory lymphokine production by asbestos.

Authors:  I Lemaire; C Dubois
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

Review 4.  Cytokines and other mediators in rheumatoid arthritis.

Authors:  J M Dayer; S Demczuk
Journal:  Springer Semin Immunopathol       Date:  1984

Review 5.  HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

Authors:  J H Ringrose
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

6.  Lack of T cell oligoclonality in enzyme-digested synovial tissue and in synovial fluid in most patients with rheumatoid arthritis.

Authors:  J M Van Laar; A M Miltenburg; M J Verdonk; M R Daha; R R De Vries; P J Van den Elsen; F C Breedveld
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats.

Authors:  K Phadke; J Carroll; S Nanda
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

8.  Epitope specificity of antibodies to type II collagen in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  M J Rowley; I R Mackay; C A Brand; J F Bateman; D Chan
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

9.  Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis.

Authors:  M C Boissier; X Z Feng; A Carlioz; R Roudier; C Fournier
Journal:  Ann Rheum Dis       Date:  1987-09       Impact factor: 19.103

10.  Cellular, molecular, and genetic characteristics of T cell reactivity to collagen in man.

Authors:  A M Solinger; R Bhatnagar; J D Stobo
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.